Roche’s Single-Dose Influenza Drug Granted FDA Approval for Children Aged 5 and Over

The logo of Swiss drugmaker Roche at its headquarters in Basel, Switzerland, on Jan. 30, 2020. Arnd Wiegmann/Reuters

Swiss healthcare company Roche’s single-dose oral tablet, Xofluza, has received approval from the U.S. Food and Drugs Administration (FDA) for the treatment of influenza in children aged five years and older, the drugmaker announced on Friday.

Xofluza, also known as baloxavir marboxil, was granted approval to treat acute uncomplicated influenza, also known as flu, in otherwise healthy children aged between five and 12 who have shown symptoms for no more than 48 hours.